Becoming Adults: One-Year Impact Findings from the Youth Villages Transitional Living Evaluation

Young adults with histories of foster care or juvenile justice custody experience poor outcomes across a number of domains, on average, relative to their peers. While government funding for services targeting these groups of young people has increased in recent years, research on the effectiveness of such services is limited, and few of the programs that have been rigorously tested have been found to improve outcomes. The Youth Villages Transitional Living Evaluation is testing whether the Transitional Living program, operated by the social service organization Youth Villages, makes a difference in the lives of young people with histories of foster care or juvenile justice custody. The program, which was renamed "YVLifeSet" in April 2015, is intended to help these young people make a successful transition to adulthood by providing intensive, individualized, and clinically focused case management, support, and counseling

Becoming Adults, Executive Summary: One-Year Impact Findings from the Youth Villages Transitional Living Evaluation

The Youth Villages Transitional Living Evaluation is testing whether the Transitional Living program, operated by the social service organization Youth Villages, makes a difference in the lives of young people with histories of foster care or juvenile justice custody. The program, which was renamed "YVLifeSet" in April 2015, is intended to help these young people make a successful transition to adulthood by providing intensive, individualized, and clinically focused case management, support, and counseling. The evaluation uses a rigorous random assignment design and is set in Tennessee, where Youth Villages operates its largest Transitional Living program. From October 2010 to October 2012, more than 1,300 young people were assigned, at random, to either a program group, which was offered the Transitional Living program's services, or to a control group, which was not offered those services. Using survey and administrative data, the evaluation team is measuring outcomes for both groups over time to assess whether Transitional Living services led to better outcomes for program group youth compared with the control group's outcomes

Risk of COVID-19 after natural infection or vaccinationResearch in context

Summary: Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health